SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. (BNAI) is rallying dramatically, fueled by an AI licensing deal in Africa and a palpable short squeeze dynamic amplified by its low float. Community sentiment is overwhelmingly bullish, with traders celebrating significant gains and anticipating further upward movement as short positions face intense pressure within the red-hot AI sector.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony (UAMY) is garnering significant attention as a crucial player in the critical minerals sector, driven by strategic operational expansions and notable increases in institutional holdings. The community is actively discussing the company's unique role as the sole integrated antimony producer outside of China and Russia, anticipating further government partnerships or investments. This focus on domestic critical mineral supply chains, vital for national security, is fostering strong bullish sentiment and expectations of continued growth.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune (ALT) is trending with a significant upward move, as the market appears to be finally re-rating the stock in light of its Breakthrough Therapy Designation for Pemvidutide and strong Phase 2 data published in The Lancet. Community discussions are heavily focused on the drug's 'best-in-class' potential for MASH and obesity, fueling intense speculation around a potential buyout or strategic partnership that would reflect a valuation comparable to sector peers.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is a trending topic amidst intense debate over the competitive landscape and regulatory environment for online betting. While the community discusses pressure from emerging prediction markets and NCAA calls for betting restrictions, a recent Massachusetts injunction against a prediction markets sports contracts is viewed as a significant positive, sparking contrasting outlooks for the company's future.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as the community eagerly awaits the highly anticipated release of 3-year data from its pivotal EMBARK study for the Duchenne muscular dystrophy gene therapy, ELEVIDYS. Many are buzzing about the potential for significant stock action and a short squeeze, while others ponder the strategic implications of the company's pre-announcement, especially given ongoing discussions about its valuation and the critical need for effective DMD treatments.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch (IMG CRYPTO) is actively trending as its dedicated community highlights consistent passive Solana rewards to holders, a unique feature designed for sustainability regardless of market direction. With recent advancements like a live audit platform and new liquidity pools, proponents are eagerly discussing its potential to break new ground in the DeFi space.

ShapeShift is a decentralized, multichain cryptocurrency platform that empowers users to swap, track, buy, and earn with over 30,000 assets across the top blockchains such as Bitcoin, Ethereum, Dogecoin, Cosmos, and more. The platform emphasizes financial sovereignty and self-custody, providing an open-source environment where users can engage with the most popular crypto tools and services to trade, earn, and hodl their digital assets. FOX token holders can submit and vote on proposals, helping to shape the future of ShapeShift.

ShapeShift FOX Token

FOX Crypto is trending with its community expressing high conviction for an imminent breakout, driven by its perceived undervaluation with a low market cap and status as a true DeFi project compared to platforms like Uniswap. Many anticipate substantial gains as "alt season" and a broader "super cycle" are widely discussed to be on the horizon for the crypto market.

Equipmentshare.Com Inc - Ordinary Shares - Class A

EquipmentShare.com Inc 

EquipmentShare (EQPT) is trending following its successful IPO and strong debut, with investors and the community actively discussing its T3 technology and national scale as potential drivers for future growth. Many see it as a disruptive force in the equipment rental market, drawing comparisons to established industry leaders.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies Inc. is trending after appointing an OpenAI expert to its board, a move widely viewed as a significant validation of its quantum-class photonic computing strategy. The community is actively discussing the potential for a substantial rally, drawing comparisons to other exploding AI-related tickers, despite ongoing debate about the company's fundamental prospects. This development is driving strong speculative interest and talks of a potential short squeeze.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

MannKind is generating significant buzz as investors eagerly await an imminent FDA decision on an Afrezza label update, aimed at simplifying dosing and potentially boosting adoption following recent reports of strong quarterly revenue. Despite this anticipation, widespread community skepticism persists regarding past stock performance and management's effectiveness, fueling lively debate and comparisons with other rapidly growing biotech companies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


decofilms13

decofilms